Health

Potential New Diagnostic and Therapeutic Target for Lung Cancer

Lung Cancer Illustration

Chinese scientists recently reported the key role of histone acetylation-regulated long noncoding RNA termed as lysosome cell death regulator (LCDR) in tumor survival, providing a potential diagnostic and therapeutic target for lung cancer.

Led by Prof. GAO Shan from the Suzhou Institute of Biomedical Engineering and Technology of the Chinese Academy of Sciences (CAS), these scientists revealed that knockdown of the LCDR in lung cancer cells could promote apoptosis. Results were published in PNAS.

Lysosome is involved in cellular homeostasis and its dysregulation has been linked to various human diseases, including cancer. LncRNAs are noncoding RNAs with lengths longer than 200 nucleotides, whose dysregulation is associated with cancer hallmarks. They drive cancer growth and survival by interacting with DNA, RNA, and protein assemblies, including the heterogeneous ribonucleic acid protein (hnRNP) family, which functions as alternative splicing, RNA stability, translation, etc.

However, whether lncRNAs and/or hnRNPs are involved in lysosome-mediated cancer survival has not been elucidated.

Proposed model for the LCDR/hnRNP K/LAPTM5 axis promoting the pathogenesis of lung cancer. Credit: GAO Shan

In this study, LCDR binds to heterogeneous nuclear ribonucleoprotein K (hnRNP K) to regulate the stability of lysosomal-associated protein transmembrane 5 (LAPTM5) transcript that maintains the integrity of the lysosomal membrane.

According to the researchers, knockdown of LCDR, hnRNP K or LAPTM5 promoted lysosomal membrane permeabilization and lysosomal cell death, thus resulting in apoptosis. LAPTM5 overexpression or cathepsin B inhibitor partially restored the effects of this axis on lysosomal cell death in vitro and in vivo.

Similarly, targeting LCDR significantly decreased tumor growth of patient-derived xenografts of lung adenocarcinoma (LUAD) and led to significant cell death using nanoparticles (NPs)-mediated systematic siRNA delivery.

Moreover, LCDR/hnRNP K/LAPTM5 were upregulated in LUAD tissues, and their co-expression showed increased diagnostic value for LUAD.

These findings shed light on LCDR/hnRNP K/LAPTM5 as potential therapeutic targets and lysosome targeting is a promising strategy in cancer treatment.

Reference: “LCDR Q:0 regulates the integrity of lysosomal membrane by hnRNP K–stabilized LAPTM5 transcript and promotes cell survival” 17 January 2022, Proceedings of the National Academy of Sciences.
DOI: 10.1073/pnas.2110428119

This work was supported by the National Natural Science Foundation of China and the Strategic Pilot Science and Technology Project of CAS etc.

Share
By
Chinese Academy of Sciences

Recent Posts

Even Moderate Exercise Can Greatly Increase Brain Size

The effects are more pronounced in brain areas with high oxygen demand. Exercise keeps both…

October 4, 2022

Caltech’s Breakthrough New Nanophotonic Chip “Squeezes” More Out of Light

Electronic computing and communications have advanced significantly since the days of radio telegraphy and vacuum…

October 4, 2022

Parallels to HIV: Another Fatal Monkey Virus Could Be Poised for Spillover to Humans

Evoking parallels to HIV, authors are calling on global health community to be vigilant. According…

October 4, 2022

Scientists Show Transmission of Epigenetic Memory Across Multiple Generations

Changing the epigenetic marks on chromosomes results in altered gene expression in offspring and in…

October 4, 2022

Spectacular Planetary-Scale “Heat Wave” Discovered in Jupiter’s Atmosphere

An unexpected ‘heat wave’ has been discovered in Jupiter’s atmosphere. It reaches a scorching temperature…

October 4, 2022

“Really Impressive” – Astronomers Capture the First Wide-Field Snapshots of X-Ray Universe

EP-WXT Pathfinder has released its first results. EP-WXT Pathfinder, an experimental prototype of a module…

October 4, 2022